Gene expression profiling in biopsied tumor tissues
View Patent ↗The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.
1. A method for predicting the likelihood of long-term survival without the recurrence of breast cancer comprising:
assaying a level of a RNA transcript of STK15 in a tissue sample obtained from a primary ductal or lobular breast tumor of a human patient;
normalizing said level against a level of at least one reference RNA transcript in said tissue sample to provide a normalized STK15 RNA level; and
predicting the likelihood of long-term survival of said patient without the recurrence of breast cancer by comparing said normalized STK15 RNA level to gene expression data obtained from reference samples derived from patients with breast cancer, wherein increased normalized STK15 RNA level is negatively correlated with increased likelihood of long-term survival without breast cancer recurrence in said patients with breast cancer.
2. The method of claim 1 further comprising assaying a level of an RNA transcript of one or more genes selected from a group consisting of: Bc12, Ki-67, GSTM1, PR, SURV, ESR1, and BAG1 in said tissue sample, normalized against a level of at least one reference RNA transcript in said tissue sample to provide a normalized RNA level of said one or more genes; and comparing said normalized RNA level of said one or more genes to gene expression data obtained from reference samples derived from patients with breast cancer, wherein increased normalized RNA level of one or more of Ki-67 and SURV negatively correlates with an increased likelihood of long-term survival without breast cancer recurrence, and increased normalized RNA level of one or more of Bc12, GSTM1, PR, ESR1, and BAG1 positively correlates with an increased likelihood of long-term survival without breast cancer recurrence.
3. The method of claim 1 wherein the breast tumor is an invasive breast tumor, and said method further comprises assaying a level of a RNA transcript of one or more genes selected from the group consisting of: FOXM1, PRAME, Bc12, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, CA9, Contig51037, RPS6K1 and Her2.
4. The method of claim 1 wherein said breast tumor is an estrogen receptor (ER) positive breast tumor.
5. The method of claim 4 further comprising assaying a level of a RNA transcript of one or more genes selected from a group consisting of : PRAME, Bc12, FOXM1, DIABLO, EPHX1, HIF1A, VEGFC, Ki-67, IGF1R, VDR, NME1, GSTM3, Contig51037, CDC25B, CTSB, p27, CDH1, and IGFBP3.
6. The method of claim 2 wherein the levels of 2 or more RNA transcripts is determined.
7. The method of claim 1 wherein said tissue sample is a fixed, wax-embedded tissue specimen.
8. The method of claim 1 , wherein said tissue sample is from a fine needle biopsy sample.
9. The method of claim 1 , further comprising creating a report based upon said normalized STK15 RNA level.
10. The method of claim 9 , wherein said report includes a prediction of the likelihood of long term survival of said patient without the recurrence of cancer.
11. The method of claim 1 , wherein said gene expression data is produced using a multivariate analysis using the Cox Proportional Hazards model.
12. The method of claim 1 wherein said assaying is done using RNA obtained from a formalin-fixed paraffin-embedded tissue sample.
13. The method of claim 1 wherein said assaying is done using reverse transcriptase polymerase chain reaction (RT-PCR).
14. The method of claim 1 , wherein said assaying is done after a ductal carcinoma has been surgically removed from a breast of said patient.
15. The method of claim 14 , wherein said ductal carcimoma is an invasive ductal carcinoma.
16. The method of claim 1 , wherein said assaying is done after a lobular carcinoma has been surgically removed from a breast of said patient.
17. The method of claim 16 , wherein said lobular carcinoma is an invasive lobular carcinoma.
18. The method of claim 1 , wherein said comparing is done by calculating a quantitative score indicating the likelihood of long-term survival without the recurrence of breast cancer of the human patient, wherein said quantitative score is calculated using said normalized STK15 RNA level of the human patient and the negative correlation between increased normalized STK15 RNA level and an increased likelihood of long-term survival without recurrence of breast cancer.